NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Laurus Labs FY26 Net Profit Surges 151% to ₹890 Cr; Declares ₹1.20 Interim Dividend
Laurus Labs reported a robust financial performance for the fiscal year ended March 31, 2026, with annual consolidated revenue growing 23% to ₹6,812.90 crore. The company's net profit for FY26 saw a massive jump of 151%, reaching ₹889.85 crore compared to ₹354.41 crore in the previous year. For the fourth quarter alone, net profit stood at ₹281.91 crore, nearly a four-fold increase from the ₹73.45 crore reported in Q4 FY25. Additionally, the board has approved a second interim dividend of ₹1.20 per share, rewarding shareholders for the strong performance.
முக்கிய அம்சங்கள்
Annual Consolidated Revenue increased by 22.7% YoY to ₹6,812.90 crore in FY26.Full-year Net Profit grew by 151% YoY to ₹889.85 crore from ₹354.41 crore in FY25.Q4 FY26 Net Profit rose to ₹281.91 crore, a significant jump from ₹73.45 crore in the year-ago quarter.Declared a 2nd interim dividend of ₹1.20 per share (60% of face value) with a record date of May 08, 2026.Earnings Per Share (EPS) for FY26 improved significantly to ₹16.47 from ₹6.65 in the previous fiscal.
👀 கவனிக்க வேண்டியவை
The significant turnaround in profitability and strong revenue growth indicate that the company's expansion and operational strategies are yielding high returns. Investors should consider holding the stock as the company demonstrates strong operational leverage and consistent dividend payouts.
Laurus Labs Clarifies Filing Lapses; Reports Strong Q2 FY26 Net Profit of ₹194.49 Cr
Laurus Labs has responded to NSE's clarification request regarding technical discrepancies in its September 2025 financial filings, attributing them to portal glitches and inadvertent selection errors. Despite these procedural lapses, the company's financial performance for Q2 FY26 shows a significant recovery, with revenue growing to ₹1,653.47 crore from ₹1,223.70 crore YoY. Net profit surged to ₹194.49 crore compared to just ₹19.95 crore in the previous year's corresponding quarter. The company has also confirmed an interim dividend of ₹0.80 per share.
முக்கிய அம்சங்கள்
Revenue from operations increased 35% YoY to ₹1,653.47 crore for the quarter ended September 30, 2025Net profit witnessed a massive jump to ₹194.49 crore in Q2 FY26 from ₹19.95 crore in Q2 FY25Board approved an interim dividend of ₹0.80 per equity share (40% of face value) for FY 2025-26Company rectified XBRL filing discrepancies and submitted revised machine-readable financial resultsH1 FY26 total income reached ₹3,260.43 crore, a significant rise from ₹2,425.72 crore in H1 FY25
👀 கவனிக்க வேண்டியவை
Investors should view the regulatory clarification as a resolution of minor procedural issues. The core focus remains on the company's strong earnings turnaround and significant profit growth, which supports a positive long-term outlook.
Laurus Labs Receives NCLT Approval for Subsidiary Restructuring and Amalgamation
Laurus Labs has received approval from the NCLT Amravati Bench for its Composite Scheme of Arrangement involving two wholly-owned subsidiaries. The plan involves demerging Unit-1 of Laurus Synthesis Private Limited (LSPL) into Sriam Labs and merging the remaining LSPL business directly into Laurus Labs Limited. The NCLT has dispensed with meetings for shareholders and creditors of the parent company, significantly streamlining the regulatory path. Meetings for unsecured creditors of the subsidiaries are now scheduled for April 06, 2026, to move the process toward final completion.
முக்கிய அம்சங்கள்
NCLT Amravati Bench allowed the First Motion Application for the scheme on February 24, 2026Unit-1 of Laurus Synthesis Private Limited to be demerged and merged into Sriam Labs Private LimitedRemaining business undertakings of LSPL to be amalgamated with the parent company, Laurus Labs LimitedMeetings of Equity Shareholders and all Creditors of the parent company (Laurus Labs) have been dispensed withMeetings for Unsecured Creditors of LSPL and Sriam Labs are directed to be held on April 06, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward corporate simplification and operational efficiency. Monitor the outcome of the unsecured creditor meetings in April as the final steps toward full integration of the CDMO business.
Laurus Labs Q3 FY26 Revenue Up 26% to ₹1,778 Cr; EBITDA Margins Expand to 27%
Laurus Labs reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,778 crores, driven by a 37% surge in the generics division. Profitability showed significant improvement as EBITDA margins expanded to 27% and PAT for the 9-month period jumped 388% to ₹610 crores. The company is aggressively investing in high-growth areas like peptides and ADCs, with a planned CAPEX of ₹1,000 crores for both FY26 and FY27. Management maintains a healthy balance sheet with a net debt-to-EBITDA ratio of 1.2x.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 26% YoY to ₹1,778 crores with Gross Margins expanding to 60.9%Generics division revenue rose 37% to ₹1,327 crores, fueled by ARV volumes and new launchesCDMO segment recorded over 50% growth in the 9-month period, despite a phased Q3 performance of ₹408 croresPlanned CAPEX of ₹1,000 crores for FY26 and FY27 to scale peptide and ADC capabilities9-month PAT surged 388% YoY to ₹610 crores, with ROCE improving to 18.5%
👀 கவனிக்க வேண்டியவை
Investors should view the margin expansion and strong CDMO growth as positive indicators of a structural shift in the business mix. Monitor the execution of the new fermentation and ADC facilities for long-term value creation.
Laurus Labs Q3 Net Profit Surges 174% YoY to ₹252 Cr; EBITDA Margins Expand to 27.3%
Laurus Labs reported a robust Q3 FY26 with revenue growing 26% YoY to ₹1,778 crore, driven by a 37% surge in the Generics division. Profitability saw a massive jump, with Net Profit increasing 174% to ₹252 crore and EBITDA margins expanding by 720 bps to 27.3%. For the 9M FY26 period, the company crossed the ₹5,000 crore revenue mark with a 104% growth in EBITDA. While the CDMO segment showed 43% growth in the 9M period, the Bio segment faced temporary scale-up challenges with a 9% decline.
முக்கிய அம்சங்கள்
Q3 FY26 Net Profit grew 174% YoY to ₹252 Cr, while 9M FY26 Net Profit surged 388% to ₹610 CrEBITDA margins improved significantly to 27.3% in Q3, up from 20.1% in the previous year9M FY26 Revenues reached ₹5,001 Cr (+30% YoY), supported by strong performance in CDMO and GenericsNet Debt leverage improved to 1.2x EBITDA despite ongoing CAPEX at 15% of salesGenerics division revenue grew 37% in Q3, led by higher ARV volumes and developed market offtake
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant margin expansion and debt reduction as signs of high operational efficiency. The strong 9M performance and the company's strategic shift toward high-value CDMO projects and Peptides/ADC platforms provide a positive long-term outlook.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Laurus Labs Q3 FY26 Net Profit Surges 172% YoY to ₹251.66 Cr; Revenue Up 25.7%
Laurus Labs reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 25.7% YoY to ₹1,778.29 crore. Net profit for the quarter witnessed a massive jump of 172.6% YoY, reaching ₹251.66 crore compared to ₹92.30 crore in the same period last year. The nine-month profit for FY26 also showed significant improvement, rising to ₹609.65 crore from ₹124.65 crore YoY. During the quarter, the company also completed strategic investments in Laurus Bio (₹35 crore) and a joint venture with KRKA Pharma (₹49 crore).
முக்கிய அம்சங்கள்
Consolidated Revenue from operations increased by 25.7% YoY to ₹1,778.29 crore in Q3 FY26.Net Profit after tax surged by 172.6% YoY to ₹251.66 crore for the quarter.Basic Earnings Per Share (EPS) improved significantly to ₹4.67 from ₹1.71 in the previous year's quarter.Company invested ₹49 crore for a 49% stake in KRKA Pharma Private Limited joint venture during the quarter.Nine-month total income reached ₹5,044.48 crore, a substantial increase from ₹3,850.19 crore in the prior year period.
👀 கவனிக்க வேண்டியவை
The strong recovery in both top-line and bottom-line figures suggests a significant turnaround in operational efficiency and market demand. Investors should maintain a positive outlook while monitoring the progress of the pending NCLT approval for the internal demerger and merger scheme.
Laurus Labs Invests ₹49 Crore in KRKA Pharma JV via Rights Issue
Laurus Labs Limited has completed an investment of INR 490 million in its joint venture, KRKA Pharma Private Limited. The company acquired 49,000,000 equity shares at a face value of INR 10 per share through a rights issue. This transaction follows the initial proposal announced on July 25, 2025. The investment demonstrates Laurus Labs' commitment to strengthening its strategic partnership and operational footprint within the JV.
முக்கிய அம்சங்கள்
Invested INR 490,000,000 (₹49 Crores) in KRKA Pharma Private LimitedAcquired 49,000,000 equity shares at a face value of ₹10 eachInvestment executed via a rights issue to maintain or increase stake in the JVFollow-up to the regulatory disclosure originally made in July 2025
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic move to bolster the company's joint venture capabilities. Monitor future earnings reports for the operational performance and contribution of KRKA Pharma to the consolidated bottom line.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
